The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Discover which Aristocrats ETF delivers the best value by fee and why cost matters for long-term returns. Learn quick tips to compare expense ratios and pick the right fund.
25,968 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Point launches a third-party origination channel for its HEI product and names Samuel Bjelac as wholesale chief, aimi...
Syscoin faces a dramatic breach after a bridge exploit minted billions of unauthorized tokens, unleashing a sharp pri...
Wearables deliver a flood of personal-health data, but turning that data into real-life action remains a hurdle as st...
A CEO’s share sale at Mineralys shines a light on insider moves ahead of a key FDA event. This guide breaks down what...
Starting with just three rental properties, I faced cash crunch and fatigue. This guide shares how disciplined borrow...
Midwest apartment markets are turning brighter as rents rise and debt costs ease. BAM Capital now offers accredited i...
A surprise stake in Marriott Vacations Worldwide has investors weighing whether marriott stock after capital offers a...
Duolingo has solid fundamentals even as its stock underperforms. This article breaks down why a duolingo stock recove...
Bed Bath & Beyond reveals a three-pilot strategy to build a housing platform after purchasing Fathom Holdings. The pl...
AI breakthroughs ignite excitement, but investors must separate hype from real value. This guide dives into how to na...
Goldman Sachs updated its governance policy to remove formal DEI criteria from director selection, aligning with peer...